| Project/Area Number |
21592083
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUJIMOTO Kiyohide 奈良県立医科大学, 医学部, 准教授 (50264867)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 一側腎尿管閉塞解除ラットモデル / ガンマラクトン低分子化合物 / ベンゾイソフラノン低分子化合物 / TNF-α / アポトーシス / ガレクチン-3 / マトリックス応答 / 血管新生 / 1型コラーゲン / CD98/4F2hc/rBAT / ガンマラクトン化合物 / ベンゾイソフラノン化合物 / リコンビナントTNF-alpha / 抗アポトーシス活性 / 急性腎障害修復と再生 / マクロファージ / rBAT heavy chain of heterodimeric aminoacid transpoter / 一側尿管閉塞・解除腎モデル / rBAT heavy chain of heterodimeric aminoacid transporter |
|---|
| Research Abstract |
Using animal model of unilateral ureteral, complete obstruction for 14 days with for six days observation after release, cellular infiltration and accumulation surrounding crossing points of bundle of descending varsa recta at the base of papillae, and propagating beneath depressed pelvic urothelial layer, was remarkably observed. Those pathologic lesions of tissue responses were tentatively called as "niches" for repair or regeneration of injured tubules. To explore"niches", beneficial treatment with recombinant rat TNF-alpha induced some proper matrix response with dominant type-1 collagen surrounding peritubular space. In contrast, treatment with novel benzoisofuranone induced another proper matrix response at "niches" with galectin-3 or rBAT positive cellular accumulation with angiogenesis and anti-apoptosis. The present studies suggested that ten times more potent benzoisofuranone compounds might be a candidate as promising medicine for intractable chronic renal allograft nephropathy
|
